‘Encouraging’ Results Seen in Patients in LAVENDER Phase 3 Trial

‘Encouraging’ Results Seen in Patients in LAVENDER Phase 3 Trial

313775

‘Encouraging’ Results Seen in Patients in LAVENDER Phase 3 Trial

Trofinetide, Acadia Pharmaceuticals’ experimental therapy, significantly reduced neurobehavioral symptoms and improved communication in girls and young women with Rett syndrome, according to top-line data from the Phase 3 LAVENDER clinical trial. These results — meeting the trial’s main and key secondary goals — were consistent across age ranges and disease severity, according to a webcast presented by Acadia. Full data are expected to be presented at an upcoming medical meeting. “These are encouraging results for patients…

You must be logged in to read/download the full post.